Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC

Abstract Background Lack of biomarkers and in vitro models has contributed to inadequate understanding of the mechanisms underlying the inferior clinical response to immune checkpoint inhibitors (ICIs) in patients with oncogene-driven non-small cell lung cancer (NSCLC). Methods The effect of small m...

Full description

Bibliographic Details
Main Authors: Weijie Ma, Jie Zeng, Shuai Chen, Yue Lyu, Kyra A. Toomey, Chinh T. Phan, Ken Y. Yoneda, Tianhong Li
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Biomarker Research
Subjects:
Tyrosine kinase inhibitor
Peripheral blood mononuclear cells
Immune cells
Oncogenic-driven
NSCLC
In vitro cytotoxicity
Online Access:https://doi.org/10.1186/s40364-021-00324-6

Internet

https://doi.org/10.1186/s40364-021-00324-6

Similar Items